Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Zenocutuzumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Zenocutuzumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Zenocutuzumab. |
| Estrone | Estrone may increase the thrombogenic activities of Zenocutuzumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Zenocutuzumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Zenocutuzumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Zenocutuzumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Zenocutuzumab. |
| Estriol | Estriol may increase the thrombogenic activities of Zenocutuzumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Zenocutuzumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Zenocutuzumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Zenocutuzumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Zenocutuzumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Zenocutuzumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Zenocutuzumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Zenocutuzumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Zenocutuzumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Zenocutuzumab. |
| Equol | Equol may increase the thrombogenic activities of Zenocutuzumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Zenocutuzumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Zenocutuzumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Zenocutuzumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Zenocutuzumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Zenocutuzumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Zenocutuzumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Zenocutuzumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Zenocutuzumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Zenocutuzumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Zenocutuzumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Zenocutuzumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Zenocutuzumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Zenocutuzumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Zenocutuzumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Zenocutuzumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Zenocutuzumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zenocutuzumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Zenocutuzumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Zenocutuzumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Zenocutuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Zenocutuzumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Zenocutuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Zenocutuzumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Zenocutuzumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zenocutuzumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Zenocutuzumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zenocutuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Zenocutuzumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Zenocutuzumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zenocutuzumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Zenocutuzumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Zenocutuzumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Zenocutuzumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Zenocutuzumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Zenocutuzumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Zenocutuzumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Zenocutuzumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Zenocutuzumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Zenocutuzumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Zenocutuzumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Zenocutuzumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Zenocutuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Zenocutuzumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Zenocutuzumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Zenocutuzumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Zenocutuzumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Zenocutuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Zenocutuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Zenocutuzumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Zenocutuzumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Zenocutuzumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Zenocutuzumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Zenocutuzumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Zenocutuzumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Zenocutuzumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Zenocutuzumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Zenocutuzumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Zenocutuzumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Zenocutuzumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Zenocutuzumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Zenocutuzumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Zenocutuzumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Zenocutuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Zenocutuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Zenocutuzumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Zenocutuzumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Zenocutuzumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Zenocutuzumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Zenocutuzumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Zenocutuzumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Zenocutuzumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Zenocutuzumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Zenocutuzumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Zenocutuzumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Zenocutuzumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Zenocutuzumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Zenocutuzumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Zenocutuzumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Zenocutuzumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Zenocutuzumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Zenocutuzumab. |